ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Search through all presentations

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...cancer-and-colorectal-cancer-in-recent-years

Body Abstract:Metastatic germ cell tumors represent a model of a curable malignant disease due to a unique chemosensitivity to cisplatin-based combination therapy resulting in long term survival rates of about 80%.

Date: 26 Sep 2014
Presenter: Carsten Bokemeyer
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Germ Cell Tumours, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...iscussant-abstracts-497O-498O-499O-and-LBA12

Date: 27 Sep 2014
Presenter: Axel Grothey
Resources: Presentation
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ly-treated-metastatic-colorectal-cancer-mCRC

AimRegorafenib, an oral multi-kinase inhibitor, improves overall survival (OS) in patients with mCRC who progressed after standard therapies. CONCUR (NCT01584830) was designed to evaluate the efficacy...

Date: 27 Sep 2014
Presenter: Tae Won Kim
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...cancer-mCRC-refractory-to-standard-therapies

AimTAS-102 is a combination of a novel oral nucleoside, trifluridine (FTD) with the thymidine phosphorylase inhibitor, tipiracil hydrochloride (TPI), which prevents the degradation of FTD, enabling sustained and effective FTD levels.

Date: 27 Sep 2014
Presenter: Eric Van Cutsem
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...etting-of-stage-II-III-colorectal-cancer-CRC

AimThe aims of Q2 were to assess whether the addition of BEV 7.5mg/kg q3/52 (12/12) to single agent CAP 1250mg/m2, 14 of every 21/7 (6/12), increases disease-free (DFS) and overall survival (OS) in CRC...

Date: 27 Sep 2014
Presenter: Rachel Midgley
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-2-trial-Spanish-Cooperative-Group-for-the-T

AimThe optimal duration and content of first-line therapy in p with mCRC once they have achieved the maximal response remains controversial. This multicenter, randomized, phase II study was aimed to...

Date: 27 Sep 2014
Presenter: Pilar García Alfonso
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ctal-cancer-Mature-data-and-subgroup-analysi

AimAIO KRK 0207 investigates which maintenance strategy, no treatment or Bev alone, is non-inferior to FP plus Bev, following a 24-week induction with FP/Ox/Bev.MethodsFollowing registration pts received induction treatment with FP/Ox/Bev.

Date: 27 Sep 2014
Presenter: Susanna Hegewisch-Becker
Resources: Abstract, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...cer.-Final-results-of-the-GERCOR-DREAM-study

AimVEGF or EGFR targeted monoclonal antibodies with chemotherapy demonstrated clinical activity in metastatic colorectal cancer (mCRC). Yet, combining these monoclonal antibodies in mCRC achieved adverse outcomes.

Date: 27 Sep 2014
Presenter: Benoist Chibaudel
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-MBC-colorectal-CRC-or-pancreatic-PaC-cancer

AimPM01183 is a promising new agent. It exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. PM01183 single-agent recommended dose ...

Date: 27 Sep 2014
Presenter: Tamara Sauri
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Drug Development, Breast Cancer, Metastatic, Colon Cancer, Rectal Cancer, Pancreatic Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-small-cell-lung-cancer-or-colorectal-cancer

AimNeurohormonal overactivity is implicated in the progression of cachexia and BBs are proposed as a potential therapy. Retrospective studies suggest that ß-blockers (BBs) may have a beneficial effect...

Date: 27 Sep 2014
Presenter: John Beadle
Resources: Abstract
Topics: Drug Development, Supportive Care, Non-Small-Cell Lung Cancer, Metastatic, Colon Cancer, Rectal Cancer